FAMILIAL HYPERCHOLESTEROLEMIA IN FRENCH-CANADIANS - TAKING ADVANTAGE OF THE PRESENCE OF A FOUNDER EFFECT

被引:43
作者
DAVIGNON, J [1 ]
ROY, M [1 ]
机构
[1] HOTEL DIEU HOSP MONTREAL,VASC MED SECT,MONTREAL,PQ,CANADA
基金
英国医学研究理事会;
关键词
D O I
10.1016/0002-9149(93)90003-U
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The frequency of familial hypercholesterolemia (FH) in the Province of Quebec is twice that observed in most population samples. In the French-Canadian population, 5 mutations in the low density lipoprotein (LDL) receptor gene account for 76% of FH cases diagnosed using clinical and biochemical criteria. One of these mutations, a > 10 kilobase (kb) deletion at the 5' end of the gene involving the promoter and exon 1, is present in 60% of FH patients studied in Montreal. This high frequency is attributable to a ''founder effect.'' Contribution of this founder effect included strategies in 17th century France for the settlement of a small number of pioneers, local incentives for early marriages and large families, and geographic and cultural isolation; these factors also favored endogamy. The > 10 kb deletion is present on only one haplotype in all patients studied so far (homozygotes and heterozygotes), a major advantage for studies relating phenotypic variation to haplotype variation in the normal LDL receptor allele to these hemizygous patients. Indeed, the presence of founder effects facilitates screening, genetic counseling, and treatment. It also confers a number of advantages for research: (1) the search for new causes of FH in the 24% unaccounted for to date; (2) the study of the geographic distribution of mutations and population movements; (3) the identification of gene-gene interactions in the etiology of disease; (4) the evaluation of factors modulating phenotypic expression and search for LDL-lowering genes; and (5) the study of genetic determinants of therapeutic response.
引用
收藏
页码:D6 / D10
页数:5
相关论文
共 27 条
  • [1] MOLECULAR GENETIC-EVIDENCE FOR A FOUNDER EFFECT IN FAMILIAL HYPERCHOLESTEROLEMIA AMONG FRENCH-CANADIANS
    BETARD, C
    KESSLING, AM
    ROY, M
    CHAMBERLAND, A
    LUSSIERCACAN, S
    DAVIGNON, J
    [J]. HUMAN GENETICS, 1992, 88 (05) : 529 - 536
  • [2] BETARD C, 1991, INFLUENCE LDL RECEPT
  • [3] BOUCHARD G, 1990, HIST SOC/SOC HIST, V23, P325
  • [4] BOUCHARD G, 1991, HIST UN GENOME POPUL
  • [5] BROWN C, 1988, HIST GENERALE CANADA
  • [6] THE RESPONSE TO LOVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS MODULATED BY APOLIPOPROTEIN-E POLYMORPHISM
    CARMENA, R
    ROEDERER, G
    MAILLOUX, H
    LUSSIERCACAN, S
    DAVIGNON, J
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (07): : 895 - 901
  • [7] CHARBONNEAU H, 1987, NAISSANCE UNE POPULA
  • [8] APOLIPOPROTEIN-E POLYMORPHISM ASSOCIATION WITH LIPOPROTEIN PROFILE IN ENDOGENOUS HYPERTRIGLYCERIDEMIA AND FAMILIAL HYPERCHOLESTEROLEMIA
    DALLONGEVILLE, J
    ROY, M
    LEBOEUF, N
    XHIGNESSE, M
    DAVIGNON, J
    LUSSIERCACAN, S
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (02): : 272 - 278
  • [9] APOLIPOPROTEIN-E POLYMORPHISM AND ATHEROSCLEROSIS
    DAVIGNON, J
    GREGG, RE
    SING, CF
    [J]. ARTERIOSCLEROSIS, 1988, 8 (01): : 1 - 21
  • [10] PHENOTYPIC HETEROGENEITY ASSOCIATED WITH DEFECTIVE APOLIPOPROTEIN-B-100 AND OCCURRENCE OF THE FAMILIAL HYPERCHOLESTEROLEMIA PHENOTYPE IN THE ABSENCE OF AN LDL-RECEPTOR DEFECT WITHIN A CANADIAN KINDRED
    DAVIGNON, J
    DUFOUR, R
    ROY, M
    BETARD, C
    MA, Y
    OUELLETTE, S
    BOULET, L
    LUSSIERCACAN, S
    [J]. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1992, 8 : 10 - 17